Related Experiment Video

Updated: Feb 26, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

8.0K

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease

Laetitia Thibault1, Olivier Rascol2, Jean-Christophe Corvol3

  • 1Clinical Research Federation, Lille University Medical Center, Lille, France.

Movement Disorders : Official Journal of the Movement Disorder Society
|July 14, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

15.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K

Related Experiment Videos

Last Updated: Feb 26, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

8.0K
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

15.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Neural Regulation01:37

Neural Regulation

43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K

Articles linked to this work by shared authors, journal, and citation graph.

One-Year Substantia Nigra R 2 * Changes across Parkinson's Disease Stages.

Movement disorders : official journal of the Movement Disorder Society·2026

Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).

Neurology·2026

A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson's disease symptoms.

Journal of Parkinson's disease·2026

Body placement of inertial measurement units differentially affects physical activity assessment accuracy in drug-naïve Parkinson's disease.

Scientific reports·2026

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026

The Costs of Parkinson's Disease in Europe: Results of the Costs of Illness in Neurology Initiative.

Movement disorders : official journal of the Movement Disorder Society·2026

Decoding Sleep Architecture from Ambulatory Basal Ganglia Signals in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Phase 2a Randomized Controlled Trial of TPN-101, A Nucleoside Reverse Transcriptase Inhibitor, in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026

Integrative Multi-Omics Analysis Reveals Convergent Epigenome and Transcriptome Changes in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Evolution of Epidemiological Studies in Movement Disorders.

Movement disorders : official journal of the Movement Disorder Society·2026

Apathy in Lewy Body Disorders: A Position Paper.

Movement disorders : official journal of the Movement Disorder Society·2026

Population Pharmacokinetic and Pharmacodynamic Analysis of Imipenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.

Drug design, development and therapy·2026

Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.

Therapeutics and clinical risk management·2026

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.

Frontiers in neuroscience·2026

Proton Pump Inhibitor-Associated Restless Legs Syndrome.

Cureus·2026

Multidimensional characterization of heterogeneity in pesticide co-exposure patterns.

Frontiers in chemistry·2026

Frustration brake failure hypothesis of substance use disorders.

Frontiers in psychiatry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us